10-Q: Intorio Corp. Reports Q3 2025 Results: Revenue Remains Low Amidst Going Concern Concerns

Intorio Corp.'s Q3 2025 results reveal minimal revenue and a net loss, raising concerns about the company's ability to continue as a going concern.

Summary

• Intorio Corp. filed its Form 10-Q for the quarterly period ended November 30, 2024.
• The company has an accumulated deficit of $106,298 as of November 30, 2024, and $77,143 as of February 29, 2024.
• For the three months ended November 30, 2024, the company generated $0 in revenue and reported a net loss of $14,293.
• For the nine months ended November 30, 2024, the company's net loss was $29,155.
• As of November 30, 2024, the company's total assets were $48,935 and current liabilities were $76,172.
• The company's management expresses concerns about its ability to continue as a going concern without additional capital resources.
• The company plans to change its name from Intorio Corp. to REDOX International Group.
• Effective May 16, 2024, there was a change in majority shareholder control.
• The company's disclosure controls and procedures were deemed ineffective as of November 30, 2024.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's lack of revenue, increasing losses, going concern concerns, and ineffective disclosure controls.

Positives

• The company converted $54,160 of debt from the previous sole officer and director into equity.
• The company is introducing Functional Medicine Laboratory Testing Items since operate.

Negatives

• The company reports $0 revenue for the three months ended November 30, 2024.
• The company has a significant accumulated deficit of $106,298 as of November 30, 2024.
• Current liabilities exceed total assets, indicating a negative working capital position.
• Management expresses concerns about the company's ability to continue as a going concern.
• The company's disclosure controls and procedures were deemed ineffective as of November 30, 2024.

Risks

• The company's ability to continue as a going concern is uncertain due to its accumulated deficit and lack of revenue.
• The company's reliance on related party loans to fund operations poses a risk if such funding is not sustained.
• The ineffectiveness of disclosure controls and procedures could lead to inaccurate or incomplete financial reporting.
• The company may not be able to raise additional capital on acceptable terms, or at all, which could restrict its business operations.
• Additional issuances of equity or convertible debt securities will result in dilution to current shareholders.

Future Outlook

The company expects to require additional capital to meet its long-term operating requirements and plans to raise additional capital through the sale of equity or debt securities.

Management Comments

• Management's plan is to obtain such resources for the Company by obtaining capital from management and significant shareholders sufficient to meet its minimal operating expenses and seeking third party equity and/or debt financing.
• Management cannot provide any assurance that the Company will be successful in accomplishing any of its plans.

Industry Context

The company is positioning itself in the functional medicine space, which is a growing area of healthcare focused on personalized and preventative approaches. The company aims to improve the domestic health management environment through diversified market services and comprehensive development.

Comparison to Industry Standards

• It is difficult to compare Intorio Corp.'s results to industry standards due to its early stage and specific focus on functional medicine.
• Larger, more established companies in the healthcare and wellness space, such as Thorne HealthTech or Life Extension, have significantly higher revenues and more diversified product offerings.
• The company's reliance on related party loans is not uncommon for early-stage companies, but it also indicates a higher level of risk compared to companies with access to traditional financing.

Management Changes

Related Party Transactions

• The previous sole officer and director loaned the Company $54,160 to pay for incorporation costs and operating expenses, which was later converted to equity.
• Since the ownership change effective May 16, 2024, to cover certain operating expenses and cash position of the company, the current shareholders advanced funds to the Company in form of short-term shareholder loans.
• As of November 30, the outstanding balance of these short-term loans was $60,543.
• During December 2024, the Company repaid $45,000 to shareholders, which reduced the amount due to related parties in the form of short-term shareholder loans.
• On January 7, 2025, and January 23, 2025, a related party provided the Company with loans of $10,000 each to cover operating expenses.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and potential dilution from future equity issuances.
• Employees face uncertainty due to the company's going concern concerns.
• Customers may be impacted by the company's ability to provide services if it cannot secure additional funding.
• Creditors face increased risk of non-payment due to the company's negative working capital position.

Next Steps

• The company intends to change its name to REDOX International Group.
• The company plans to register its own trademark.
• The company will seek additional capital through the sale of equity or debt securities.
• The company will seek to obtain short-term loans from its directors.

Key Dates

Keywords

financial statements, going concern, net loss, revenue, Intorio Corp, REDOX International Group, Form 10-Q, related party transactions, functional medicine